Quantum-Si operates in proteomics, the large-scale study of proteins, and is attempting to bring single-molecule protein sequencing to a benchtop platform that can sit in any laboratory. The company's value proposition is built on replacing complex, multistep workflows with real-time, kinetic-based detection that delivers dynamic, functional protein insights. Its current Platinum instrument line provides a commercial foundation, but the strategic thesis increasingly rests on Proteus, its next-generation platform.
The medium-term outlook hinges on whether Quantum-Si can convert a technology lead into durable commercial traction. Management's stated roadmap calls for Proteus to deliver meaningful advantages over Platinum — including automation, higher throughput, better signal-to-noise ratio, longer read lengths, and broader amino acid coverage. If validated at scale, these attributes could strengthen the company's competitive moat against larger, better-funded incumbents in proteomic analysis and mass spectrometry. However, the company's still-nascent revenue base underscores that market positioning today is defined more by pipeline potential than by share of wallet. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The single most important upcoming event is the commercial launch of Proteus, expected by the end of 2026, with an Early Access Program anticipated to begin in the summer of 2026. On September 15, 2026, the company announced it had demonstrated sequencing with detection of 18 amino acids on integrated Proteus instruments and reaffirmed its goal of demonstrating all 20 amino acids during 2026. Management has signaled that the pace of improvement could allow the commercial kit to include all 20 amino acids at launch — a development that would materially strengthen the product's appeal for protein identification and post-translational modification (PTM) analysis, which examines chemical changes to proteins after they are made.
Investor attention will also center on earnings releases, with the next report estimated for early November 2026. Forward-looking commentary on launch readiness, early customer funnel building, and the Platinum Pro upgrade program will likely matter more than near-term revenue, given the company's transition-year positioning.
On the analyst front, sentiment remains constructive but divided. H.C. Wainwright reiterated a Buy rating and a $4.00 price target in late September 2026, while Alliance Global Partners maintained a Buy rating but lowered its target to $1.90 in August 2026. Canaccord Genuity has held a more cautious Hold rating with a $1.00 target. The resulting consensus leans toward Buy, with average 12-month price targets clustered roughly in the $2.28–$2.50 range, though the wide dispersion between the high and low targets reflects genuine uncertainty about commercialization timing and scale.
Quantum-Si's trajectory is closely tied to the broader funding and spending cycle in life sciences research. Academic, clinical, biopharmaceutical, and government customers drive demand for proteomics tools, and their budgets tend to be sensitive to interest rates and broader economic conditions. In a higher-rate environment, slower capital equipment purchasing cycles can delay instrument adoption, while softer biopharma funding could temper consumable pull-through.
On the positive side, the long-term shift toward precision medicine and biomarker discovery continues to expand the addressable market for protein analysis. Artificial intelligence is also becoming a more prominent part of the company's strategy, particularly for interpreting the large datasets Proteus is expected to generate. Management has highlighted the potential to leverage advanced AI tools to expand PTM detection capabilities over time. These structural tailwinds are counterbalanced by intense competition from established mass spectrometry vendors and emerging protein-sequencing rivals, many of which command greater financial and marketing resources.
Looking toward 2026 and beyond, the central question is whether Quantum-Si can cross the chasm from technology demonstration to commercial adoption. The company has clearly stated that 2026 is a transition year focused on delivering Proteus, preparing the market, and preserving financial strength. A successful launch, strong early customer engagement, and expansion of the amino acid detection roadmap to all 20 amino acids would position 2027 as the year when commercialization begins to translate into revenue growth.
Longer-term themes include the evolution of the company's cost structure and path to profitability, the sustainability of gross margins as the business scales, and disciplined capital allocation. Because the company remains pre-profit and generates limited revenue, its ability to fund operations without dilutive capital raises is a critical watch item. Management has emphasized preserving financial strength, but the potential need for future financing remains a stated risk.
Consensus expectations reflect this balance of promise and execution risk. Analysts generally see substantial long-term upside embedded in the Proteus narrative, yet the wide range of published price targets — from $1.00 to $4.00 — signals that sentiment could shift rapidly based on launch execution, customer adoption, and cash-runway developments. Competitive threats from larger, better-resourced players and the pace of regulatory or technology transitions will continue to shape the medium-term outlook.
One tool I’ve found useful when monitoring catalyst-driven names like this is the Trend Prediction Engine. It offers AI-powered forecasts that help identify whether an asset may trend bullish, bearish, or sideways over the coming weeks or months. In my view, adding this quantitative layer complements fundamental research on volatile development-stage companies and supports more informed timing decisions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Oscillator for QSI moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 25 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QSI as a result. In 83 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
QSI moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for QSI crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 160 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 94 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.616) is normal, around the industry mean (4.142). P/E Ratio (-2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices